,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['breast', 'corin', 'enhertu']
a few sobering points amid all the #asco22 excitement over enhertu benefit in her2-low breast cancer: there's still much variability in ihc 0 and 1+ scoring ... and the trial enrollment didn't live up to the meeting theme of "advancing equity" 
Journalist: Personalized medicine, genomics, cancer; Managing editor: @PrecOncNews 
https://t.co/t2jQRuYQgf 
@GenomeWeb 
https://t.co/MOrpOLPAKt